MorphoSys was founded in Martinsried near Munich in 1992. The founders included Dr. Simon Moroney, today’s CEO of the Company and Prof. Dr. Andreas Plückthun. Today, MorphoSys is one of the world’s leading biotechnology companies in the area of fully human antibodies.
Year | Event |
|---|
1992 | Company founded in Martinsried/Munich, Germany |
1997 | First commercial partnership with Pharmacia-Upjohn Move to the Innovation and Start-up Center for Biotechnology (IZB) Martinsried |
1999 | IPO at the Frankfurt Stock Exchange Start of an extensive partnership with Bayer AG Patent dispute begins with Cambridge Antibody Technology |
2000 | Presentation of the HuCAL antibody library First HuCAL patent granted |
2001 | Presentation of the HuCAL GOLD antibody library Start of a strategic partnership with Schering AG |
2002 | MorphoSys achieves a settlement of the CAT patent dispute Dr. Simon E. Moroney receives the Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal Republic of Germany) |
2003 | Start of a partnership with Pfizer HuCAL antibodies to combat Alzheimer’s produce positive preclinical results |
2004 | Start of a strategic partnership with Novartis Presentation of the new research antibodies division, Antibodies by Design Inclusion in the technology index TecDAX MorphoSys achieves break even |
2005 | The first HuCAL antibodies used in clinics Acquisition of Biogenesis Group strengthens the research segment First partnership with a Japanese pharmaceutical group |
2006 | Acquisition of Serotec Group further strengthens the research segment HuCAL antibodies to combat Alzheimer’s disease are used in clinics |
2007 | MorphoSys announces development of new antibody platform technology MorphoSys and Novartis forge one of the industry’s largest pharma-biotech R&D collaborations |
2008 | First proprietary therapeutic antibody MOR103 enters clinical trials MorphoSys unveils new antibody library, HuCAL PLATINUM First HuCAL antibody enters phase 2 clinical trials |
2009 | MorphoSys signs first infectious disease alliance with Daiichi-Sankyo |
| 2010 | First proprietary therapeutic antibody in a patient setting First in-licensing of a clinical antibody from Xencor Aquisition of Sloning BioTechnology MorphoSys presents new antibody technology arYla |
| 2011 | MOR202 enters clinical development MorphoSys presents new antibody technology Ylanthia MorphoSys signs first industrial biotechnology alliance with Novozymes |
| 2012 | MorphoSys announces positive clinical data for MOR103 in RA and MOR208 in CLL With gantenerumab from Roche, the first partnered antibody program reaches late stage development MorphoSys celebrates its 20th anniversary MorphoSys signs first Ylanthia-based therapeutic partnership |
| 2013 | MorphoSys completes sale of AbD Serotec to Bio-Rad |
